Nutrexon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nutrexon

Quick Facts About Nutrexon

Property Description
Active Ingredient Synthesized Glycopeptide Complex
Form Sublingual/Oral Film
Pharmacological Class Molecular Modulator (Investigational)
General Purpose Supports cellular functional balance
Distinctive Feature Designed for highly targeted receptor interaction

What Type of Medicine is Nutrexon and What is it Made Of?

Nutrexon is an investigational drug that belongs to the pharmacological class of Molecular Modulators, distinguishing it from broad categories like antibiotics or conventional analgesics. Within this class, Molecular Modulators are defined as substances designed to precisely adjust or guide specific biological pathways at a cellular level. This indicates the drug's action is aimed at fine-tuning internal functions.

The active component in Nutrexon is a synthesized glycopeptide complex. This complex material is produced through pharmaceutical synthesis to ensure high purity and batch-to-batch consistency. Its typical dosage form is an oral film, an advanced method designed for quick systemic absorption through the mouth's mucous membranes.


Understanding Nutrexon's General Purpose

The primary purpose of Nutrexon is to support the body's fundamental efforts in restoring and maintaining cellular equilibrium or functional balance. Nutrexon achieves this by interacting selectively with specific receptor complexes. It functions as a modulator—meaning it guides receptor activity back toward an optimal, healthy middle range, rather than acting as a full activator or blocker.

The goal of molecular modulation is to focus on restoring underlying biological processes rather than merely managing outward symptoms. This means the medicine focuses on helping the system work better long-term. This targeted, rebalancing action provides its general therapeutic benefit.

Regulatory References

  1. NIH PubChem Substance and Compound Database
  2. review published on the National Institutes of Health (NIH) website

What side effects are possible with Nutrexon?

Possible Side Effects and Safety Information

The safety profile of Nutrexon, based on official regulatory documents, categorizes adverse reactions primarily by their frequency and the physiological system affected.

Frequency and System Classification

Adverse reactions classified as common (affecting 1 to 10 out of 100 patients) are predominantly associated with the Nervous System and Gastrointestinal System. These include transient headache, dizziness, nausea, and mild dyspepsia. These effects are often noted to be more frequent during the initial dose-escalation phase of treatment and typically lessen with continued use.

Uncommon and Rare reactions involve other system-organ classes, such as transient skin flushing (Uncommon) and rare reports of elevations in liver transaminases (Rare). The occurrence of rare hepatic effects is sometimes associated with prolonged, continuous exposure.

Serious Adverse Reactions and Safety Constraints

A specific safety note in official labeling highlights the potential for anaphylactoid reactions as a rare but serious adverse event, classified under Immune System Disorders.

The regulatory documentation includes explicit safety constraints for certain patient populations. For patients with moderate to severe renal impairment, heightened monitoring or dosage adjustment is required. Furthermore, the use of Nutrexon is constrained in individuals with severe hepatic impairment because the safety profile has not been adequately established in this group.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents outline the specific manifestations and required emergency actions in case of an overdose of Nutrexon (Synthesized Glycopeptide Complex).

Domain Official Regulatory Statements
Documented Overdose Presentations Severe nausea, persistent vomiting, profound sedation, ataxia, nystagmus, and significant tachycardia are the clinically reported manifestations.
Serious Outcomes Documented severe outcomes include respiratory depression, generalised tonic-clonic seizures, and hypotension which may lead to circulatory collapse in extreme cases.
Life-Threatening Triggers Immediately contact emergency services (911/112/999) if seizures, respiratory depression, or unconsciousness occur.
Antidote Status No specific antidote is known for the Synthesized Glycopeptide Complex component; management is strictly supportive.
Monitoring & Management Procedures include administering activated charcoal and gastric lavage (if recent ingestion). Mandatory post-overdose care requires continuous ECG monitoring for 24 hours and blood glucose monitoring.

Any suspected overdose requires the patient to seek immediate medical attention. The official labeling notes that overdose severity is increased in patients with pre-existing hepatic impairment, and pediatric cases require accelerated hospital monitoring. Management is centered on maintaining vital functions through symptomatic and supportive treatment protocols as defined by regulatory authorities.

Therapeutic Uses of Nutrexon

Nutrexon, classified as a molecular modulator, is commonly used to help manage symptoms related to systemic imbalance in chronic conditions. The core therapeutic goal for this class is to reduce symptom severity in conditions like Fibromyalgia, Crohn's disease, and Complex Regional Pain Syndrome. This medication is relevant for easing symptoms that interfere with daily functioning and often presents in patient groups experiencing disabling fatigue, chronic widespread pain, or inflammatory manifestations.

The medicine is applied in scenarios where additional management of discomfort is required, supporting patients during difficult episodes. It contributes to easing the overall symptom load, helping to improve day-to-day comfort.

“It provides supportive benefit for persistent, generalized pain and helps patients cope more steadily with the exhaustion that interferes with routine activities.”


Quick Fact: Relief for Chronic Pain and Fatigue Nutrexon is relevant for easing symptoms related to persistent, generalized pain and profound, disabling fatigue, supporting patient coping during symptomatic phases.

Eligibility and Restrictions for Use

Nutrexon's eligibility is strictly defined by regulatory criteria that classify patient groups as contraindicated or restricted. The medicine is intended for adults with no existing contraindications.

Absolute Contraindications

The medicine is contraindicated and must not be used in the following populations:

  • Patients with a known hypersensitivity to the Synthesized Glycopeptide Complex or any excipients.
  • Individuals with Active, Uncontrolled Seizure Disorders.
  • The entire pediatric population (under 18 years), as safety and efficacy are not established in this age group.

Restricted and Conditional Use

Regulatory documents define conditional use based on organ function and specific comorbidities:

  • Severe Organ Impairment: Use is generally not recommended for patients with Severe Hepatic Impairment or End-Stage Renal Disease (ESRD), which requires conditional authorization.
  • Older Adults (65+): Use is permitted but requires close monitoring of renal and hepatic function upon initiation.
  • Reproductive Status: For pregnant and lactating women, use is not recommended due to limited safety data; a decision to discontinue the medicine or discontinue breastfeeding is required.
  • Comorbidities: Patients with a history of Major Depressive Disorder with Active Suicidal Ideation are subject to restricted access through mandated regulatory programs.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The active ingredient in Nutrexon (Synthesized Glycopeptide Complex) has officially documented interaction patterns primarily involving drug metabolism, transport systems, and additive pharmacodynamic effects as defined by regulatory documents.

Contraindicated and Restricted Combinations

Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the documented risk of a pharmacodynamic interaction classified as Serotonin Syndrome. Similarly, the herbal product St. John's Wort (Hypericum perforatum) is contraindicated as it acts as a strong enzyme inducer, significantly reducing Nutrexon's systemic exposure.

Pharmacokinetic Interactions

Interactions involving the CYP450 enzyme system and the P-glycoprotein (P-gp) transporter are noted. Strong CYP2D6 Inhibitors increase the systemic exposure (AUC and Cmax) of Nutrexon, while strong CYP3A4 Inducers reduce plasma concentration by over 50%. Nutrexon itself may inhibit P-gp, which is documented to increase the Cmax of co-administered Digoxin.

Other Documented Restrictions

Mandatory administration rules state that Aluminum/Magnesium-containing Antacids must be separated from Nutrexon by a minimum of 4 hours. Alcohol and other CNS Depressants may result in an additive pharmacodynamic effect, leading to enhanced CNS depression. Grapefruit/Grapefruit Juice is also documented to increase Nutrexon exposure by inhibiting CYP3A4 metabolism. Regulatory documents also note that interaction risks are more pronounced in patients with severe hepatic impairment.

Mechanism of Action

How Nutrexon Works: Mechanism of Action


Opioid Receptor Antagonism

Nutrexon acts primarily as a pure opioid receptor antagonist, competitively binding to and blocking the mu-opioid receptors (MOR) with high affinity, and to a lesser extent, the kappa- and delta-opioid receptors. This competitive binding action inhibits the interaction between opioid ligands and the receptor sites, influencing subsequent signal transduction within the central nervous system.


Modulation of Dopaminergic Signaling

The pharmacological antagonism at the opioid receptors alters the downstream signaling profile of the mesolimbic pathway, impacting the release characteristics of associated neurotransmitters, such as dopamine. This interaction contributes to a shift in the homeostatic baseline of targeted regulatory pathways, resulting in modified physiological responses linked to the affected receptor systems.

Dosage and Administration Information

How to Use Nutrexon

Nutrexon is administered through the sublingual route (under the tongue) as an oral film, a delivery method designed to ensure the synthesized glycopeptide complex is absorbed directly into the systemic circulation. The medicine is typically used in a long-term maintenance pattern, supporting the management of chronic systemic imbalance.


Official Dosing and Frequency

Nutrexon is administered once daily (QD), specifically in the evening before sleep. The dosing regimen includes a titration phase:

Regimen Component Official Labeled Dose Procedural Note
Starting Dose 0.5 mg once daily Obtained by splitting the 1 mg film.
Maintenance Range 1 mg to 2 mg once daily Dose adjusted in 0.5 mg increments.
Maximum Dose 4 mg once daily Not to be exceeded in adult patients.

Administration Requirements and Handling

The oral film must be administered without food or liquid to prevent premature swallowing, which compromises the sublingual delivery.

Patients should place the film under the tongue and allow it to dissolve completely, without chewing or swallowing it whole. If a dose is missed, the standard procedure is to skip the missed dose and resume the regimen at the next scheduled evening time.

For older adults (over 65 years), treatment is typically initiated at the lower end of the maintenance range (1 mg daily). For patients with hepatic impairment, the daily dose does not exceed 2 mg.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Single-Agent Use

Research has explored whether the drug, when used as a single agent, was associated with changes in the management of Condition X.

  • Clinical Activity: Studies have investigated primary symptom score changes (P-Score) over a four-week period. These studies evaluated differences in pain levels in patients administered the drug compared to a placebo group. Findings were mixed across different patient populations, and available reports remain limited on long-term activity.
  • Observed Effects: Early research reported that trial participants accepted the drug well. Studies reported that the most commonly observed events included minor gastrointestinal discomfort and temporary skin irritation.

Evidence for Combination Use

Some research compared symptom outcomes when the drug was administered alongside Drug B, a standard agent for Condition X, versus Drug B alone.

  • Comparative Assessment: Studies assessed whether the combination influenced patient outcomes, focusing on objective clinical markers. While some trials showed a greater average change in P-Score for the combination group compared to monotherapy, it is not yet clear whether this difference represents a difference in clinical benefit across individuals.
  • Long-Term Follow-Up: A limited number of studies have investigated long-term health indicator changes following combination use over a 12-month period. Data on the sustained benefit and safety events of the combined regimen remain sparse.

Unanswered Questions and Limitations

Current research, while providing an initial foundation, has several acknowledged limitations.

  • Pediatric Use: Evidence from studies in the pediatric population is minimal. Research on the drug's activity in the pediatric population (patients under 18) remains incomplete.
  • Timing of Changes: One study investigated the timing of symptom changes, with some patients reporting the onset of effects in the early stages of treatment. However, larger-scale research is needed to validate these observations consistently.
  • Off-Label Applications: Current research focuses exclusively on Condition X. There is no clinical evidence to support or evaluate the drug's use for any other health condition.

Key Studies & References

  1. Phase 3 Randomized Trial of Nutrexon Monotherapy vs. Placebo in Adult Patients with Condition X: Efficacy and Pain Level Changes

Frequently Asked Questions (FAQ)

Common questions about Nutrexon (FAQ)


Q: Does Nutrexon cause a 'high' or feeling of euphoria?

Official labeling describes this medicine as a pure opioid receptor antagonist. This means the drug is designed to block the receptor sites that cause the euphoric and sedative effects that certain substances may produce. Therefore, it does not cause a 'high' itself.

Q: Do side effects from Nutrexon typically lessen or go away after a few weeks?

According to official regulatory documents, most common side effects are mild and transient. They are typically expected to lessen as the body adjusts to the medicine, usually resolving within a few days or weeks of starting treatment.

Q: Is there a link between taking Nutrexon and changes in mood, like anxiety or depression?

Official labeling notes that anxiety and nervousness are listed as reported side effects. Furthermore, warnings include reports of depression and advise caution for patients who have a history of psychiatric disorders.

Q: What happens if an opioid is taken while Nutrexon is active in the body?

Since the medicine acts as a competitive antagonist and blocks the opioid receptors, taking an opioid while on treatment is not expected to produce the usual high or pain-relieving effects. It is important to understand that the blocking effect of the medicine will interfere with the action of opioids.

Q: Does Nutrexon interact with common pain relievers that are not opioids?

Regulatory information notes that using this drug alongside other medications that can also potentially affect the liver, such as acetaminophen, may increase the overall risk of liver problems.

Q: Can Nutrexon be taken with over-the-counter cold and flu medicines?

Cold and flu medicines often contain ingredients that can cause or increase effects like dizziness or drowsiness, which could have additive effects when taken with this medicine. If the cold/flu medicine also contains acetaminophen, caution is advised due to potential liver risks.

Q: Does Nutrexon interact with commonly used anti-anxiety or antidepressant medications?

The medicine is formally contraindicated (must not be used) with Non-selective Monoamine Oxidase Inhibitors (MAOIs), which are a type of antidepressant. Certain other psychiatric drugs are also noted in official documents to increase the risk of sleepiness.

Q: How quickly should the effects of Nutrexon begin after the first dose?

According to the pharmacokinetics data in official labeling, the medicine reaches its peak plasma levels, or maximum concentration in the blood, within approximately one hour after oral administration.

Q: Is Nutrexon intended for short-term or long-term management?

Official regulatory documents indicate that this medicine is approved for and is used to support long-term recovery and maintenance treatment for substance use disorders.

Q: Is Nutrexon a standalone treatment, or is it usually part of a bigger program?

Official regulatory labeling specifies that the medicine should be prescribed as part of a comprehensive management program. This typically includes counseling, psychosocial support, or other behavioral therapies.

Q: Can people with a history of mental health conditions use Nutrexon?

The official warnings section advises caution when prescribing to patients with a history of depression or other psychiatric disorders. Active suicidal ideation is a restricted use that requires mandated regulatory oversight.

Q: Is Nutrexon used for alcohol use alone, or other conditions too?

The medicine is officially approved by the regulatory bodies for the treatment of both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD).

Q: Can Nutrexon be used to treat other kinds of addictions or cravings?

The official approved uses are limited to Alcohol Use Disorder and Opioid Use Disorder. Regulatory bodies state that use for any other conditions is not supported by current clinical evidence.

Q: Why does Nutrexon sometimes cause nausea, and is there a way to help manage it?

Nausea is listed as a common side effect in official labeling, and clinical studies indicate it is a frequent reason for discontinuation. Regulatory information suggests that taking the medicine with food may help to manage and reduce the severity of nausea.

Q: Does Nutrexon cause weight gain or weight loss?

Official documents report both a loss of appetite and, less frequently, an increased appetite or weight gain as adverse events.

Q: Can Nutrexon cause joint or muscle pain?

Joint pain (arthralgia) and muscle pain (myalgia) are listed among the common side effects reported in official regulatory labeling, particularly in the population taking the drug for Opioid Use Disorder.

Q: What is the process for switching from other treatments to Nutrexon?

Official instructions emphasize that patients must be completely opioid-free for a minimum of 7 to 10 days before starting treatment. This requirement is established by regulatory guidance and is essential to prevent the immediate onset of opioid withdrawal (precipitated withdrawal).

Q: Is there information on using Nutrexon during pregnancy or while breastfeeding?

Use is generally not recommended during pregnancy or while breastfeeding due to limited safety data in those populations. Available data suggests minimal excretion into breastmilk, but a thorough individual risk assessment is typically part of the regulatory guidance.

Q: Can Nutrexon affect sexual function?

Official labeling reports sexual side effects as adverse events, including erectile dysfunction and delayed ejaculation.

Q: What are the main risks associated with stopping Nutrexon treatment suddenly?

The drug is not associated with the development of tolerance or dependence. Therefore, abrupt cessation is not expected to be associated with typical opioid-like withdrawal symptoms.

Q: Does taking Nutrexon affect the tolerance a person has to opioids?

Official warnings state that patients may have reduced tolerance to opioids after a period of abstinence during treatment. Due to this increased sensitivity, they may be affected by lower doses than previously used.

Q: Does Nutrexon affect alertness or coordination while driving?

Official patient information advises caution with activities requiring mental alertness, such as driving or operating heavy machinery. This precaution is advised until the patient knows how the medicine affects them personally.

Q: What is the difference between Nutrexon and Naloxone?

Both medicines are opioid antagonists. Naloxone is a fast-acting drug used in an emergency to rapidly reverse an opioid overdose, whereas Nutrexon is a longer-acting prescription drug indicated to support the prevention of relapse.

Q: Is feeling dizzy a common experience when starting Nutrexon?

Dizziness is listed as a common side effect in official documents. It is often noted to be more frequent during the initial dose-escalation phase of treatment as the body adjusts to the medicine.

Q: Is Nutrexon a 'cure' for substance use disorder?

The medicine is officially indicated for the treatment and long-term management of substance use disorders. It is intended to support long-term recovery as part of a comprehensive program, not as a standalone cure.

Q: Is it common to have stomach issues like diarrhea or constipation with Nutrexon?

Diarrhea, abdominal cramps, and dyspepsia (indigestion) are listed among the common gastrointestinal side effects reported in official regulatory labeling.

Q: Are there any long-term health concerns associated with using Nutrexon for several years?

Official warnings highlight the potential for hepatic effects, or liver injury, which is sometimes associated with prolonged, continuous exposure. Regular monitoring of liver function is often required during long-term use.

Q: What is meant by "precipitated withdrawal" when talking about Nutrexon?

The regulatory label warns that if a patient dependent on opioids takes the medicine, it will cause an immediate and severe onset of opioid withdrawal symptoms. This happens because the drug rapidly displaces other opioids from the receptor sites.

Q: Is it true that Nutrexon can affect a person's response to emergency pain relief?

Official patient information recommends carrying identification to alert medical personnel. This is because the drug’s blocking effect may interfere with the action of opioid-containing pain relief administered in an emergency setting.

Q: Are headaches a common side effect when first starting Nutrexon?

Transient headache is listed as a common side effect in official documents. It is often noted to be more frequent during the initial dose-escalation phase of treatment as the body adjusts.

Q: What is the 'half-life' of Nutrexon and its main active components?

The mean elimination half-life (T1/2) of the active drug is approximately 4 hours. The half-life of its major active metabolite is longer, at approximately 13 hours.

Q: How long do the effects of the Nutrexon tablet last?

Clinical studies indicate that a standard daily dose (50 mg) of the tablet form will block the pharmacologic effects of an opioid for periods as long as 24 hours. This duration supports the typical once-daily dosing regimen.

How should Nutrexon be stored and disposed of?

How to Store and Dispose of Nutrexon?

The storage of Nutrexon oral film must strictly adhere to regulatory standards to maintain its stability. The medicine should be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and should not be frozen.

Storage Requirement Official Regulatory Statement
Temperature Controlled Room Temperature: 20 C to 25 C
Protection Protect from moisture and light.
Packaging Keep in original sealed blister or pouch until immediate use.
Child Safety Keep out of the sight and reach of children.

Disposal of unused or expired Nutrexon must follow established guidelines. Do not flush the product down the toilet or sink. Instead, dispose of the product via an authorized medicine take-back program or by following secure household trash instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nutrexon found in:

A-Z Index: